Products & Services
Company Description
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohns disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
Business Contact Information
- Phone
- 650-421-7200
- Fax
- No data
- Website
- http://www.dermira.com
- No data
- Address
- 275 Middlefield Road, Menlo Park, California, 94025, United States
Industry & Classification
- Industry Name Level 1
- No data
- Industry Name Level 2
- No data
- Industry Name Level 3
- No data
NAICS Codes
No data
SIC Codes
No data
Company Details
- Employees
- 95
- Annual Revenue
- $50.0M
- Established
- No data
- Total Funding
- No data
- Latest Funding
- No data
Related Companies
Own this business?
Keep your profile accurate — or ask us to take it down. We acknowledge requests within 7 days and resolve them within 30 days.
Prefer email? privacy@facturmfg.com